• +1-646-491-9876
    • +91-20-67278686

    Search

    Dilated Cardiomyopathy-Pipeline Review H2 2017

    Dilated Cardiomyopathy-Pipeline Review H2 2017

    • Report Code ID: RW0001881461
    • Category Life Sciences
    • No. of Pages 64
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Dilated Cardiomyopathy-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Dilated Cardiomyopathy-Pipeline Review H2 2017 provides an overview of the Dilated Cardiomyopathy (Cardiovascular) pipeline landscape.

    Dilated cardiomyopathy (DCM) is a condition in which the heart's ability to pump blood is decreased because the heart's main pumping chamber the left ventricle is enlarged and weakened. Symptoms include Fatigue and weakness Shortness of breath (dyspnea) lightheadedness dizziness or fainting persistent cough or wheezing lack of appetite sudden weight gain from fluid retention and swelling (edema) in legs ankles and feet. Risk factors include family history alcoholism hypertension cocaine abuse and metabolic disorders such as thyroid disease or diabetes.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Dilated Cardiomyopathy-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Dilated Cardiomyopathy (Cardiovascular) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Dilated Cardiomyopathy (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Dilated Cardiomyopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase II Phase I Preclinical Discovery and Unknown stages are 2 3 2 2 and 1 respectively. Similarly the Universities portfolio in Preclinical stages comprises 1 molecules respectively.

    Dilated Cardiomyopathy (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Dilated Cardiomyopathy (Cardiovascular) .
    - The pipeline guide reviews pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Dilated Cardiomyopathy (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Dilated Cardiomyopathy (Cardiovascular) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Dilated Cardiomyopathy (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Dilated Cardiomyopathy (Cardiovascular) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Dilated Cardiomyopathy (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Dilated Cardiomyopathy-Overview
    Dilated Cardiomyopathy-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Dilated Cardiomyopathy-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Dilated Cardiomyopathy-Companies Involved in Therapeutics Development
    Array BioPharma Inc
    Capricor Therapeutics Inc
    Hemostemix Ltd
    Kasiak Research Pvt Ltd
    MyoKardia Inc
    Sanofi
    Vericel Corp
    Dilated Cardiomyopathy-Drug Profiles
    ACP-01-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARRY-797-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BC-007-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CAP-1002-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DCM-2-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Drugs for Dilated Cardiomyopathy-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ixmyelocel-T-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LUS-1-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Refacell-DCM-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAR-440181-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    YS-1402-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Dilated Cardiomyopathy-Dormant Projects
    Dilated Cardiomyopathy-Product Development Milestones
    Featured News & Press Releases
    May 10 2017 Vericel Receives FDA Regenerative Medicine Advanced Therapy Designation for Ixmyelocel-T for the Treatment of Advanced Heart Failure Due to Ischemic Dilated Cardiomyopathy
    Feb 02 2017 First Subjects Dosed in MyoKardia Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491
    Dec 02 2016 MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491
    Aug 30 2016 Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
    Apr 04 2016 Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet
    Mar 29 2016 Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions
    Mar 28 2016 Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
    Mar 10 2016 Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy
    Jan 29 2015 Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T
    Dec 19 2013 Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia
    Dec 17 2013 Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack
    Apr 19 2013 Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T
    Jun 06 2012 Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting
    May 10 2012 Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients
    May 07 2012 Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Dilated Cardiomyopathy H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products under Development by Universities/Institutes H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Universities/Institutes H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Dilated Cardiomyopathy-Pipeline by Array BioPharma Inc H2 2017
    Dilated Cardiomyopathy-Pipeline by Capricor Therapeutics Inc H2 2017
    Dilated Cardiomyopathy-Pipeline by Hemostemix Ltd H2 2017
    Dilated Cardiomyopathy-Pipeline by Kasiak Research Pvt Ltd H2 2017
    Dilated Cardiomyopathy-Pipeline by MyoKardia Inc H2 2017
    Dilated Cardiomyopathy-Pipeline by Sanofi H2 2017
    Dilated Cardiomyopathy-Pipeline by Vericel Corp H2 2017
    Dilated Cardiomyopathy-Dormant Projects H2 2017

    List of Figures

    Number of Products under Development for Dilated Cardiomyopathy H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Array BioPharma Inc
    Capricor Therapeutics Inc
    Hemostemix Ltd
    Kasiak Research Pvt Ltd
    MyoKardia Inc
    Sanofi
    Vericel Corp

    Request for Sample

    Report Url http://www.reportsweb.com//dilated-cardiomyopathy-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//dilated-cardiomyopathy-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//dilated-cardiomyopathy-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments